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Abstract
Background: Leishmaniasis is a common parasitic disease in Southern Europe, caused by
Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially
attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in
vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum
strains, derived from the same infected animal, during in vitro and in vivo passages and after host
treatment with meglumine antimoniate.
Results: SbV-IC50 values for strains from two distinct isolates from the same host and one stock
after two years of culture in NNN medium and posterior passage to hamster were similar (5.0 ±
0.2; 4.9 ± 0.2 and 4.4 ± 0.1 mgSbV/L, respectively). In contrast, a significant difference (P < 0.01, t
test) was observed between the mean SbV-IC50 values in the stocks obtained before and after
treatment of hosts with meglumine antimoniate (4.7 ± 0.4 mgSbV/L vs. 7.7 ± 1.5 mgSbV/L). Drug-
resistance after drug pressure in experimentally infected dogs increased over repeated drug
administration (6.4 ± 0.5 mgSbV/L after first treatment vs. 8.6 ± 1.4 mgSbV/L after the second) (P <
0.01, t test).
Conclusions: These results confirm previous observations on strains from Leishmania/HIV co-
infected patients and indicate the effect of the increasing use of antimony derivatives for treatment
of canine leishmaniasis in endemic areas on the emergence of Leishmania antimony-resistant strains.
Background
Leishmaniasis, a protozoan parasitic disease, is endemic
in 88 countries, with an estimated yearly incidence of 1–
1.5 million cases of cutaneous leishmaniasis and 500,000
cases of visceral leishmaniasis. Three hundred and fifty
million people are estimated to be at risk, and there is an
overall prevalence of 12 million cases [1]. Zoonotic viscer-
al leishmaniasis occurs mainly in Latin America, the Med-
iterranean Basin and Asia. The parasite responsible for this
disease is Leishmania infantum and the dog is the main res-
ervoir. Leishmaniasis has re-emerged in recent years be-
cause of the increase in risk factors, some of which are
related to HIV infection and intravenous drug use. In
Western Europe the cumulative number of cases of Leish-
mania/HIV co-infections, reported to the WHO up to De-
cember 1999 was 1627 [2]. Canine leishmaniasis in
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problem. The dog is one of the main hosts responsible for
the spread of visceral leishmaniasis, which was initially
only in rural areas, but is now extending to suburbs. Sig-
nificant foci are located on the periphery of cities where
small gardens encourage the presence of sandfly vectors
[2]. The main treatment for dogs is through pentavalent
antimonials. Nevertheless these drugs usually produces
only temporary remission of clinical signs, and relapses
are frequent [3]. Other alternatives such as amphotericin
B [4], aminosidine [5] and allopurinol [6] have also
shown variable results. The ineffectiveness of treatment
for cutaneous and visceral leishmaniasis is attributable to
host physiology, the compound and its preparation and
the susceptibility of the parasite strain to the drugs [7–11].
Grogl et al. [12] induced promastigote resistance to Pen-
tostam in vitro in Leishmania strains from American cuta-
neous leishmaniasis, by discontinuous exposure of
promastigotes to the drug. These authors observed that af-
ter repeated in vitro passages and in vivo infection, resist-
ance was stable in the absence of drug pressure. The
Figure 1
Flow chart for the origin of L. infantum stocks, derived from the same infected dog, after several in vitro and in vivo passages.
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tigotes of Leishmania strains obtained during a second ep-
isode of anthroponotic [10] or zoonotic human visceral
leishmaniasis [9,13] has also been observed. In addition,
Gramiccia et al [3] observed that the in vivo activity of SbV
in mice infected with L. infantum strains from dogs treated
with meglumine antimoniate was lower than in mice in-
fected with strains obtained before the dogs were treated.
Here we evaluated the in vitro susceptibility to SbV of in-
tracellular amastigotes of L. infantum strains, derived from
one infected animal. These strains were obtained in a
number of studies that involved repeated in vitro cultiva-
tion, hamster and canine experimental infections and two
courses of treatment with meglumine antimoniate. This
study aims to determine the stability of in vitro SbV suscep-
tibility of L. infantum stocks during successive in vitro and
in vivo passages and the role of host treatment in this sus-
ceptibility.
Results
The in vitro susceptibility to SbV of two L. infantum strains
(MCAN/ES/92/BCN-82 and MCAN/ES/92/BCN-83), si-
multaneously isolated from bone marrow and lymph
node aspirate from the same dog were almost identical
(IC50: 5.0 ± 0.2 and 4.9 ± 0.2 mgSbV/L). Also, the SbV-
IC50 for MCRI/ES/94/BCN-328 (4.4 ± 0.1 mg/L) was very
similar to that of the original strain (BCN-83) (Figure 1),
despite repeated in vitro passages and hamster inocula-
tion.
The mean IC50 in these strains from untreated hosts
(BCN-82, BCN-83 and BCN-328) (4.7 ± 0.4 mgSbV/L)
was lower (P < 0.01, t test) than in five strains (BCN-335,
BCN-336, BCN-323, BCN-329 and BCN-331) isolated af-
ter dogs had been treated with meglumine antimoniate
(7.7 ± 1.5 mgSbV/L). The IC50 was also lower in strains
obtained after one treatment course with meglumine an-
timoniate (BCN-335 and BCN-336) (6.4 ± 0.5 mgSbV/L)
than in strains obtained after a second course with this
drug (BCN-323, BCN-329 and BCN-331) (8.6 ± 1.4 mgS-
bV/L) (Table 1).
The promastigote growing capacity of strains BCN-82,
BCN-83 and BCN-328 was higher than in strains from
dogs treated with meglumine antimoniate (Table 1).
Discussion and Conclusions
Leishmania isolates from an infected host have a multi-
clonal composition with an heterogeneous expression of
different phenotypes such as drug resistance [12], viru-
lence [14] or growth capacity in vitro. The variations in
clonal composition difficult comparison and interpreta-
tion of results from studies performed with different
strains and, even, with the same strain after repeated pas-
sagesin vitro or in vivo. Differences in the expression of cer-
tain phenotypes, such as "virulence" or "growth rate in
vitro" may modify the clonal composition of the strain
during successive passages. This, in turn, may modify the
expression of other phenotypes like drug resistance.
In our study no differences were observed in SbV suscepti-
bility of intracellular amastigotes of L. infantum strains
isolated from untreated animals, despite repeated in vitro
passages and hamster infection. In contrast, SbV suscepti-
bility was lower in strains isolated after treatment with
meglumine antimoniate of experimentally infected dogs.
It is worth emphasising that the Priorat, where the strain
was first isolated, is a rural region, with a high prevalence
of canine leishmaniasis [15] and where dogs were rarely
treated at the time when the first isolation was performed.
We can thus assume that the drug pressure received by
strains BCN 82 and BCN-83 was very low.
The in vitro growth capacity of Leishmania varies from one
isolate to another and isolates that are initially difficult to
grow adapt to the culture after repeated passages, proba-
bly because of the selection of phenotypes with higher
growing rate. The promastigote growth rate in NNN and
Schenider's culture media of all strains isolated after treat-
ment was lower than in the original strain (BCN-83),
without modification in the course of successive passages.
This suggests that the selected clones more resistant to SbV
also had a different promastigote growth rate phenotype
Our results correlates with previous studies performed
with other designs, methodologies and Leishmania species
Table 1: Growth rate of promastigotes and SbV susceptibility of 
intracellular amastigotes, of L. infantum strains, after repeated in 
vitro and in vivo passages and dogs treatment with meglumine 
antimoniate.
Strain Code Growtha IC 50 (mg SbV/L)b IC 50 Mean 
values
MCAN/ES/92/BCN 82 61 5.0 ± 0.2 Untreated 
animals
MCAN/ES/92/BCN 83 69 4.9 ± 0.2 4.7 ± 0.4
MCRI/ES/94/BCN 328 57 4.4 ± 0.1
MCAN/ES/95/BCN 335 24 6.7 ± 0.5
MCAN/ES/95/BCN 336 22 6.0 ± 0.2 Treated 
animals
MCAN/ES/98/BCN 323 29 9.7 ± 0.3 7.7 ± 1.5
MCAN/ES/98/BCN 329 31 9.1 ± 0.6
MCAN/ES/98/BCN 331 28 6.9 ± 0.5
a: promastigotes × 106/mL Schneider's medium + 20% HIFCS, after 
three days of culture b: values are the means ± the standard deviation 
of three counts in two separate assays (n = 6)Page 3 of 5
(page number not for citation purposes)
BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/11[3,9,10,12,13]. The study reinforces that the SbV suscepti-
bility of Leishmania strains is stable over in vitro and in vivo
passages, in the absence of drug pressure. Moreover, SbV
susceptibility decreases after host treatment with meglu-
mine antimoniate. We conclude that the increasing use of
antimony derivatives in veterinary practice in Southern
Europe will lead to a rapid overspread of L. infantum SbV-
resistant strains.
Material and Methods
Parasites and drug
L. infantum strains BCN-82 and BCN-83 were isolated
from bone marrow and lymph node aspirate from an
asymptomatic dog, from the Priorat region (Spain), a
highly endemic area for canine leishmaniasis [15]. BCN-
83 was maintained for almost two years by repeated pas-
sages in NNN medium, it was then inoculated by intra-
peritoneal injection into one hamster. After three months
the parasite was isolated again from the hamster spleen in
NNN medium (coded as BCN-328) and promastigotes
were used to experimentally infect dogs [16] for subse-
quent pharmacokinetic studies [17,18].
Dogs were treated with meglumine antimoniate (Glucan-
time, Rhône Mérieux) (20.4 mg of Sb/kg/12 h), for two
10-day periods, each separated by an interval of 10 days
[17].
After a temporary remission of the symptoms, all dogs re-
lapsed and two isolates were obtained from dogs A (BCN-
335) and C (BCN-336). All dogs were treated again using
a meglumine antimoniate liposomal formulation at a
dose equivalent to 9.8 mgSb/kg/24 h for two 10-day peri-
ods, separated by an interval of 10 days [18]. Positive cul-
tures were obtained again from dogs A (BCN-329), C
(BCN-323) and F (BCN-331) at a range of times after
treatment. (Figure 1)
Parasite isolation and in vitro maintenance was done
through passages in NNN medium. Promastigotes from
NNN were cultured in Schneider's insect medium at 26°C
with 20% heat inactivated foetal calf serum (HIFCS).
Their growth rate was then calculated, to establish the op-
timal conditions for in vitro susceptibility tests [19].
The pentavalent antimony used in in vitro assays was a so-
lution of SbV in 8% hydrochloric acid at a concentration
of 1 mg/mL (Varian Associates, Inc. Palo Alto, CA). Fur-
ther working dilutions were performed in culture media.
Previous assays demonstrated that the distinct working di-
lutions of HCl have no effect on the growing capacity of
cultures [19].
Susceptibility test
The in vitro susceptibility tests to SbV were performed on
intracellular amastigotes, cultured in the murine mono-
cyte-macrophage cell line RAW 264.7 (American Type
Culture Collection) in RPMI-1640 medium (Bio-Whittak-
er 12-1115; Boehringer-Ingelheim, Verriers, Belgium)
with 10% of HIFCS in a 8 LabTeck Chamber Slide System
(Nalge Nunc, Hamburg, Germany) as described previous-
ly [19]. Cells exposed to serial dilutions of the drug were
cultured for 2 days at 37°C in a 5% CO2 atmosphere. Drug
activity was evaluated by calculating the percentage of in-
fected cells. Counting was performed at three places in the
well and each assay was performed twice.
The concentration of SbV that produced a 50% reduction
in infected cells (IC50) was determined from least-squares
linear regression of growth rate or percentage vs. log anti-
mony concentration.
Student's unpaired test was used to determine the statisti-
cal significance of the values obtained.
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